0001209191-16-129924.txt : 20160628 0001209191-16-129924.hdr.sgml : 20160628 20160628171611 ACCESSION NUMBER: 0001209191-16-129924 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160624 FILED AS OF DATE: 20160628 DATE AS OF CHANGE: 20160628 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cascadian Therapeutics, Inc. CENTRAL INDEX KEY: 0001412067 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 260868560 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2601 FOURTH AVENUE STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: (206) 801-2100 MAIL ADDRESS: STREET 1: 2601 FOURTH AVENUE STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: Oncothyreon Inc. DATE OF NAME CHANGE: 20070927 FORMER COMPANY: FORMER CONFORMED NAME: Biomira CORP DATE OF NAME CHANGE: 20070911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SPIEGELMAN DANIEL K CENTRAL INDEX KEY: 0001238403 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33882 FILM NUMBER: 161736830 MAIL ADDRESS: STREET 1: 3172 PORTER DRIVE CITY: PALO ALTO STATE: CA ZIP: 94034 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-06-24 0 0001412067 Cascadian Therapeutics, Inc. CASC 0001238403 SPIEGELMAN DANIEL K C/O CASCADIAN THERAPEUTICS, INC. 2601 FOURTH AVE., SUITE 500 SEATTLE WA 98121 1 0 0 0 Restricted Share Unit (RSU) 2016-06-24 4 A 0 54347 0.00 A Common Stock 54347 54347 D Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs. 100% vests on the one-year anniversary of the Transaction Date, subject to acceleration under certain circumstances. /s/ Julia M. Eastland as attorney-in-fact for Daniel K. Spiegelman 2016-06-28